News of Note—Zhejiang Huahai Pharmaceutical gets some cash; Merck wins an award

Microphone
(Pixabay)

> Zhejiang Huahai Pharmaceutical, whose valsartan APIs have been banned from the U.S. after being found to contain a potential carcinogen, has received a $43 million infusion from the city government of Linhai in the eastern province of Zhejiang, where the company is based. Story

> Sun Pharma has invested Rs 120 crore ($1.6 million) to add a manufacturing line to its plant in Guwahati, India, to produce sterile drugs. Story

> U.K.-based Acacia says it received an FDA complete response letter for Barhemsys, its drug candidate for post-operative nausea and vomiting, after the agency identified a deficiency with its contract manufacturer during a pre-approval inspection. Release

> Merck Research Laboratories has received a Green Chemistry Challenge Award from the American Chemical Society for its sustainable approach to the development and manufacturing of doravirine—a compound recently approved by the FDA for the treatment of HIV. Release

> Quotient Sciences has invested $15 million in a 45,000-square-foot facility near Philadelphia for early-phase formulation development and clinical trial manufacturing. Release